Navigation Links
Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
Date:10/7/2008

Study Showed Larazotide Acetate Prevented Immunologic Changes Induced by

Gluten in Patients with Celiac Disease Additional Data Indicates Potential in Treating Inflammatory Bowel Disease

ORLANDO, Fla., Oct. 7 /PRNewswire/ -- Alba Therapeutics Corporation presented results from two clinical studies this week at the American College of Gastroenterology (ACG) 2008 Annual Scientific Meeting. Data from study CLIN 1001-004, the first Phase IIa trial conducted in celiac disease and the first to assess the prevention of immunologic changes in celiac disease, showed that larazotide acetate (AT-1001) successfully demonstrated prevention of gluten-induced immunologic changes in celiac patients.

Results from the study showed that larazotide acetate is the first pharmacologic agent to prevent changes in blood mononuclear cell populations (specifically T-reg cells and B Cells) and other markers of immunological change associated with active celiac disease. This data suggests that larazotide acetate offers potential as a future treatment of celiac disease. Results from a second poster presented at ACG showed that larazotide acetate also inhibited the effect of inflammatory cytokines, including tumor necrosis factor (TNF-alpha) and interleukin (IL-4) on intestinal epithelial permeability, in vitro, further suggesting that the product offers potential as a future treatment for inflammatory bowel disease (IBD).

Larazotide Acetate is a novel, non-absorbed peptide currently being studied in Phase IIb trials for the treatment of celiac disease. Larazotide acetate has the potential to become the first approved medicine to treat celiac disease and has been granted "Fast Track" designation from the U.S. Food and Drug Administration (FDA) for this indication.

Celiac disease affects approximately one percent of individuals in the United States and Europe, or approximately 6.5 million individuals. The only accepted management for the dise
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
2. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
3. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
4. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
5. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
6. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
7. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
10. Tobira Therapeutics Inc. Receives US Patent for TBR-652
11. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2008)...ww.christmasseals.org to learn more, make a donat...SHINGTON, Nov. 17 Milli...month, courtesy of the American Lung Association. ...ual fundraising tradition dating back to 1907 when...culosis. , , "Most Americans alive today ...
(Date:11/18/2008)...E, Va., Nov. 18 Forty-t...ed at a November national forum to consider cuttin...c health and national economy from outbreaks of da...ed today. , , Among those innovations: , ...merican kitchen table that detects highly contagio...
(Date:11/18/2008)...ed study will enroll newly diagnosed, elderly AML ...wswire/ -- Celator Pharmaceuticals today announced...omized Phase 2 clinical study of CPX-351 (Cytarabi...th newly diagnosed acute myeloid leukemia (AML). ,...eldman, MD at the Weill Medical College of Cornel...
(Date:11/13/2008)...Study Suggests Nutritional Supplements Prior to Su...re-USNewswire/ -- Identifying,malnutrition before ...dy,contouring will significantly decrease surgical...scar quality and boost patient energy levels,acco...and Reconstructive,Surgery(R), the official medica...
Breaking Medicine Technology:American Lung Association Celebrates 101st Annual Christmas Seals Campaign 242 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference 314 1Nitec Pharma AG Announces Appointments of CEO 26 CFO in Preparation for Launch of Lodotra 28R 29 311 1Nitec Pharma AG Announces Appointments of CEO 26 CFO in Preparation for Launch of Lodotra 28R 29 311 2Nitec Pharma AG Announces Appointments of CEO 26 CFO in Preparation for Launch of Lodotra 28R 29 311 3Society for General Microbiology 161st Meeting University of Edinburgh 217 1Society for General Microbiology 161st Meeting University of Edinburgh 217 2A drug sensitive traffic cop tells potassium channels to get lost 364 1A drug sensitive traffic cop tells potassium channels to get lost 364 2
..., Germany, May 31, 2007- Results from various,clin...n patients,with advanced hepatocellular carcinoma,...tablets will be presented at the Annual,Meeting of...in,Chicago, USA from June 1 - 5, 2007. , On this o...ts,will be held on June 4, 2007. Starting at aroun...
...f Abstracts Reflects Continued Growth of Eisai,s,C...1, 2007 /PRNewswire/ -- Eisai,announced today that...eir oncology pipeline compounds have been accepted...cal Oncology (ASCO),annual meeting. ASCO takes pla...ts reveal a growing and diverse oncology clinical,...
Other Medicine Technology:Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 2Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 3Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 4
(Date:11/21/2008)...an, fresh from basic training and now serving over...e life he saved by donating his rare blood type. ...c of Korea (PRWEB) November 21, 2008 -- A local Ko...nation saved her life, met for the first time when... , ,Airman Tamarias Pope, 8th Security Forces Squa...
(Date:11/21/2008)...ork together to stop abusive behavior, experts say... Behavior that was once dismissed as "kids being k...unting research shows the negative effects on both...nals, schools, parents and even kids themselves ar...ng behavior. , "Bullying shouldn,t be consider...
(Date:11/21/2008)...ty of Texas Health Science Center at Houston will ... Studies (TEXAS), to promote geriatrics training f...rd from the Donald W. Reynolds Foundation and $1.2... to teach geriatric medicine principles to everyon...ng physicians. With the reach of Lyndon B. Johnson...
(Date:11/21/2008)...FirstCall/ -- The Providence Service,Corporation ...rris, the Company,s,Chief Operating Officer, has ...s. Mr. Norris, appointment fills the vacancy left...ger and returns the board to six members. Mr.,No... , Mr. Norris, age 41, has been with Provid...
Breaking Medicine News(10 mins):Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 2Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 3Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3
...armaceuticals Inc (RPI) has received a tentative a...sinopril is recommended for hypertension, either a...anti-hypertenive agents. It is also used as adjunc...t failure and patients who do not respond to diure...
...s of drugs based on a widely used anticancer drug,...fects in the laboratory and in mice, according to ...eresting for the treatment of these tumors. // Pr...were extremely active in blocking the same cell ta...
...ro, Cipro. That's been the mantra of the media as ...ds who weren't -- clamor for the potent antibiotic...eaper and widely available medications can be used... penicillin. Although alternatives exist, Cipro is...
...ental anti-cancer drug has shown effectiveness in ...o a new report. Researchers say the drug probably ...seful for treating other types of cancer. Dr. Anto...esda, Maryland, and colleagues tested the drug, de...
Other Medicine News:
Weight: 10.1 kg, Interior Dimensions (WxDxH): 31.1 x 13.6 x 15.3 cm, Exterior Dimensions (WxDxH): 44.6 x 22.4 x 20.5 cm, Capacity: 4 - 50 mL conical tubes, 2 - 300 x 35 mm bottles, 4 - 150 x 35 mm b
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
Medicine Products: